2025-523265-15-00
Not Yet Recruiting
Phase 1
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid Arthritis
Candid Therapeutics Inc.2 sites in 1 country9 target enrollmentDecember 16, 2025
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Candid Therapeutics Inc.
- Enrollment
- 9
- Locations
- 2
- Status
- Not Yet Recruiting
- Last Updated
- 4 months ago
Overview
Brief Summary
No summary available.
Investigators
Clinical Operations Team
Scientific
Candid Therapeutics Inc.
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (2)
Loading locations...
Similar Trials
Not Yet Recruiting
Phase 1
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.2023-510356-23-00Novartis Pharma AG76
Active, Not Recruiting
Phase 1
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors2024-513716-95-00Nec Oncoimmunity AS6
Recruiting
Phase 1
A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1)2023-507377-17-00Microbiotica Limited27
Recruiting
Phase 3
Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis2022-501788-41-00Abbvie Deutschland GmbH & Co. KG40
Recruiting
Phase 2
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and PharmacokineticsNCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72